The peptide appears to support healthy tissue repair without promoting excessive or disorganized growth
Results vary depending on individual metabolism, skin condition, and lifestyle factors
While clinical trials have provided valuable insights, further research is should determine the optimal use of these agents in different heart failure populations
If youre exploring broader support for long-term vitality, the Healthy Aging Supplements collection is a natural place to start
In the larger SELECT trial in 2023, patients with heart failure, atherosclerotic disease, and overweight or obesity, treated with semaglutide 2.4 mg showed reduction in major adverse cardiac events (MACE) and heart failure end points regardless of heart failure subgroup being HFrEF or HFpEF [56,57,58]